G. C. G. Hugenholtz

Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?

R. Porte, T. Lisman, G. C. G. Hugenholtz, 2015, Blood reviews.

The platelet and platelet function testing in liver disease.

R. Porte, T. Lisman, G. C. G. Hugenholtz, 2009, Clinics in liver disease.

Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen

R. Porte, T. Lisman, G. C. G. Hugenholtz, 2016, Journal of thrombosis and haemostasis : JTH.

Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation

R. Porte, T. Lisman, G. C. G. Hugenholtz, 2015, Journal of thrombosis and haemostasis : JTH.

Susceptibility of Human Pancreatic &bgr; Cells for Cytomegalovirus Infection and the Effects on Cellular Immunogenicity

P. de Vos, M. Engelse, E. D. de Koning, 2012, Pancreas.

TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation

R. Porte, J. Meijers, T. Lisman, 2013, Thrombosis and Haemostasis.